Immunocytochemistry/ Immunofluorescence: CCL2/MCP1 Antibody [NBP1-07035] - MCP1 antibody was tested in HeLa cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 ...read more
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
PBS, 30% glycerol
0.1% Sodium Azide
Immunogen affinity purified
This MCP1 antibody is useful for Immunocytochemistry/Immunofluorescence and Western blot, where a band is seen at ~16 kDa. In ICC/IP secretory vesicles staining was observed in HeLa cells. IHC-Fr and B/N applications are reported in research publications with PMIDs 22402584 and 22778093 respectively. The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
16 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
small inducible cytokine A2 (monocyte chemotactic protein 1, homologous tomouse Sig-je)
small inducible cytokine subfamily A (Cys-Cys), member 2
MCP-1 (monocyte chemoattracctant protein-1, also called C-C motif chemokine 2 or CCL2) is a secreted protein belonging to intercrine beta (chemokine CC) family and it specifically act as a chemotactic factor to attracts monocytes, CD4+ T cells, NK cells as well as for CCR2 expressing cells, but not neutrophils. Both hematopoietic and non-hematopoietic cells that include monocytes/macrophages, dendritic cells, astrocytes, endothelial cells and fibroblasts express MCP-1, and monocytes/macrophages are the major source of MCP-1 in peripheral blood. Besides, expression at acute inflammation sites, MCP-1 is upregulated in chronic inflammation, including autoimmune disease, atherosclerosis, cancer, and chronic infection. MCP-1 has been implicated in both pro-inflammatory and anti-inflammatory responses, and is a potential intervention point for the treatment of various inflammatory/autoimmune diseases (multiple sclerosis, atherosclerosis, insulin-resistant diabetes, rheumatoid arthritis and lupus nephritis), cancers (breast and prostate cancer) and HIV-1/AIDS.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.